Showing 1871-1880 of 5771 results for "".
- Noveome Biotherapeutics Announces Preliminary Results of its Phase 1 Trial Evaluating Intranasal Delivery of ST266 In Glaucoma Suspect Patientshttps://modernod.com/news/noveome-biotherapeutics-announces-preliminary-results-of-its-phase-1-trial-evaluating-intranasal-delivery-of-st266-in-glaucoma-suspect-patients/2479275/Noveome Biotherapeutics announced preliminary results of a phase 1 open label clinical trial to establish the safety of ST266 when delivered intranasally in glaucoma suspect patients. The trial was conducted at the University of Pennsylvania by Ahmara Ross, MD, PhD, and Kenneth Shindler, MD, PhD,
- Glaukos Announces Australia’s TGA Regulatory Approval for Preserflo MicroShunthttps://modernod.com/news/glaukos-announces-australias-tga-regulatory-approval-for-preserflo-microshunt/2479276/Glaukos Corporation announced that the Therapeutic Goods Administration (TGA) of Australia has granted regulatory approval for the Preserflo MicroShunt intended for the reduction of IOP in eyes of patients with primary open-angle glaucoma where IOP remains uncontrollable while on maximum tolerate
- Ocuphire Announces Appointment of Jay S. Pepose, MD, PhD, to Its Board of Directorshttps://modernod.com/news/ocuphire-announces-appointment-of-jay-s-pepose-md-phd-to-its-board-of-directors/2479272/Ocuphire Pharma announced the appointment of Jay S. Pepose, MD, PhD, to its Board of Directors. Concurrent to Dr. Pepose’s appointment at Ocuphire’s annual shareholder meeting on June 7, Alan Meyer, MBA, retired from his role on the Board of Directors, having served since April 2018. “We a
- Kala Pharmaceuticals Announces Eysuvis Now Covered by OptumRxhttps://modernod.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-by-optumrx/2479263/Kala Pharmaceuticals announced that OptumRx, one of the largest pharmacy benefit managers (PBM) in the United States, has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 21, 2021. “We are pleased to announce
- VSY Biotechnology Announces Launch of the Enova C Haptic Model IOLhttps://modernod.com/news/vsy-biotechnology-announces-launch-of-the-enova-c-haptic-model-iol/2479260/VSY Biotechnology announced the launch of the Enova C Haptic Model IOL. Enova is the first and only 100% glistening-free, dry-packed hydrophobic acrylic IOL, according to VSY Biotechnology. The lens requires no warming or special conditioning before surgery. The composition of Enova mater
- Oyster Point Announces Preclinical Study Results and Pipeline Expansion With ETF Gene Therapy for Ocular Surface Diseaseshttps://modernod.com/news/oyster-point-announces-preclinical-study-results-and-pipeline-expansion-with-etf-gene-therapy-for-ocular-surface-diseases/2479258/Oyster Point Pharma announced the expansion of its pipeline with the introduction of Enriched Tear Film (ETF) Gene Therapy and proof-of-concept in vivo study results from its first gene therapy candidate, OC-101. ETF Gene Therapy is a proprietary adeno-associated virus (AAV) based
- Bausch Health And Clearside Biomedical Announce FDA Filing Acceptance For Xiperehttps://modernod.com/news/bausch-health-and-clearside-biomedical-announce-fda-filing-acceptance-for-xipere/2479252/Bausch Health Companies and Bausch + Lomb, along with Clearside Biomedical, announced that the FDA has accepted the resubmitted new drug application for Xipere (triamcinolone acetonide suprachoroidal injectable suspension). FDA determined that the filing is a Class 2 resubmission and therefore as
- GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of Lumevoq Versus Natural Historyhttps://modernod.com/news/gensight-biologics-announces-publication-of-indirect-comparison-showing-treatment-effect-of-lumevoq-versus-natural-history/2479249/GenSight Biologics announced that the journal Frontiers in Neurology has published results of the indirect comparison of the evolution of visual outcomes in patients treated with Lumevoq gene therapy with the spontaneous evolution in natural history (NH) studies of Leber hereditary optic
- iHealthScreen Announces CE Certification for iPredict Automated AI Systemhttps://modernod.com/news/ihealthscreen-announces-ce-mark-for-ipredict-automated-ai-system-for-early-diagnosis-of-dr-amd-and-glaucoma-suspect/2479244/iHealthScreen announced that it is the first company in the US to receive a CE certification for simultaneous diagnosis of diabetic retinopathy (DR), age related macular degeneration (AMD), and glaucoma suspect screening, according to a company news release. Using the iPredict System,
- GenSight Biologics Announces Case Report Showing Visual Recovery after GS030 Optogenetic Treatmenthttps://modernod.com/news/gensight-biologics-announces-nature-medicine-case-report-showing-visual-recovery-after-gs030-optogenetic-treatment/2479243/GenSight Biologics announced that the journal Nature Medicine has published the first case report of partial recovery of visual function in a blind patient with late-stage retinitis pigmentosa (RP). The subject is a participant in the ongoing PIONEER phase 1/2 clinical trial of GenSight